Brief: Theratechnologies Announces New Preclinical Findings For Its Lead Investigational Peptide-Drug Conjugate Th1902 For The Potential Treatment Of Metastatic Cancers
21/06/2021 14:21
June 21 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES ANNOUNCES NEW PRECLINICAL FINDINGS FOR
ITS
LEAD INVESTIGATIONAL PEPTIDE-DRUG CONJUGATE TH1902 FOR THE
POTENTIAL TREATMENT OF METASTATIC CANCERS
* THERATECHNOLOGIES INC - RESULTS DEMONSTRATE THAT TH1902
HAS
BETTER ANTI-METASTATIC ACTIVITY WHEN COMPARED TO DOCETAXEL ALONE
Source text for Eikon: ID:nGNX1gQl26
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process